Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease

ConclusionsOverall, RTX appears to be both efficacious and well-tolerated as second- or third-line therapy for patients with non-infectious/non-malignant orbital inflammation.
Source: Journal of Ophthalmic Inflammation and Infection - Category: Opthalmology Source Type: research